Trial to compare efficiency of a drug used to reduce blood loss in surgical procedures when given through veins before start of surgery versus when sprayed at the site of surgery.
Not Applicable
- Conditions
- Health Condition 1: null- Total blood loss in total hip replacement
- Registration Number
- CTRI/2018/02/012030
- Lead Sponsor
- Sunhsine hospitals
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Informed consent
Those undergoing primary,unilateral hip replacement.
Exclusion Criteria
1.History of reported allergy to tranexamic acid
2.Patients who had been administered anticoagulants and antiplatelet drugs preoperatively
3.Ischemic heart disease
4.chronic renal failure
5.A history of hip surgery
6.Thromboembolic episodes
7.Rheumatoid arthritis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Total blood loss <br/ ><br>Change in hematocrit levels at 2nd postoperative day <br/ ><br>Operation timeTimepoint: Total blood loss <br/ ><br>Change in hematocrit levels at 2nd postoperative day <br/ ><br>Operation time
- Secondary Outcome Measures
Name Time Method 1.Transfusion rates <br/ ><br>2.Deep venous thrombosis <br/ ><br>3.Pulmonary embolisation ratesTimepoint: 1.5th post operative day <br/ ><br>2.90 days <br/ ><br>3.90 days